We also found that high-risk patients might be more sensitive to TMZ therapy, which may be related to their active IFN pathway down-regulating MGMT level and increasing the sensitivity of glioma cells to TMZ (Shen et al., 2015). This evidence concerns the gene IFNA1 and central nervous system cancer.